Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen, Inc. (NQ: BIIB )

220.99 +2.77 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 12, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 769,052
Open 218.58
Bid (Size) 215.18 (1)
Ask (Size) 222.50 (1)
Prev. Close 218.22
Today's Range 218.58 - 222.17
52wk Range 187.16 - 351.86
Shares Outstanding 147,000,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
7 F-Rated Stocks to Avoid Now
The following equities may be household names, but current market conditions mean they’re definitely stocks to avoid now. 
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
  This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga

Performance

YTD
-9.48%
-9.48%
1 Month
+3.01%
+3.01%
3 Month
+10.99%
+10.99%
6 Month
+2.98%
+2.98%
1 Year
-35.13%
-35.13%

More News

Read More
Covid Exposed A 'Brain Health Pandemic' — Here's How Biotech Stocks Like Biogen, Sage Therapeutics Could Help
Via Investor's Business Daily
Is This Company In A Special Position Even As The COVID-19 Pandemic Affects Cell-Based Therapy Industry?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Biogen (BIIB) Stock Dips Following Q2 Earnings Report
Via InvestorPlace
7 Cheap Blue-Chip Stocks to Buy Before They Rebound
Via InvestorPlace
How Is The Market Feeling About Biogen?
Via Benzinga
Bill Gates, Jeff Bezos Unite To 'Change The Course' Of Neurological Disorder Impacting 6.5 Million Americans
Via Benzinga
Here's How Much $100 Invested In Biogen 15 Years Ago Would Be Worth Today
Via Benzinga
A Monoclonal Antibody Treatment For ALS Could Begin Human Trials By 2023, According To Pasithea
Via Benzinga
7 Undervalued S&P 500 Stocks to Buy Before Wall Street Catches On
Via InvestorPlace
Recap Of Tuesday's Biotech Catalysts - End of The Day Summary
Via Benzinga
FDA Accepts Biogen's Submission For Neurodegenerative Disease Drug Under Priority Review
Via Benzinga
Daily Biotech Pulse: EU Approval For AbbVie's Ulcerative Colitis Treatment, Angion Biomedica Evaluates Alternatives, Clinical Hold For Immuron's Bacterial Infection Candidate
Via Benzinga
FDA Accepts Biogen’s New Drug Application and Grants Priority Review of Tofersen for a Rare, Genetic Form of ALS
From Biogen Inc.
Via Globe NewsWire
As Snap Spooks Market, Here Are The Hits & Misses Of Q2 Reporting Season
Via Benzinga
Biogen Whale Trades Spotted
Via Benzinga
With All Eyes On Lecanemab Read Out In Alzheimer's, Uncertainty Overshadows Biogen's Q2 Beat
Via Benzinga
Benzinga Before The Bell: Baidu Beats Tesla, Finland Sells $47.5M Bitcoins, Tesla's Bitcoin Sale And Other Top Financial Stories Thursday, July 21
Via Benzinga
Tesla to $1,175? Here Are 5 Other Price Target Changes for Thursday
Via Benzinga
Biogen Reveals $900M Settlement In Whistleblower's MS Drug Kickbacks Lawsuit Days Before Trial
Via Benzinga
Why Baker Hughes Shares Dropped 8%; Here Are 64 Biggest Movers From Yesterday
Via Benzinga
Stranger Things Do Happen As Netflix Surprises Investors
Via Benzinga
The Daily Biotech Pulse: CDC AdComm Backs Novavax COVID-19 Vaccine, European Approval For PTC Therapeutics' Gene Therapy, Merck's Keytruda Flunks In Head, Neck Cancer Study
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.